Astellas Hits Sagent, Strides With Adenoscan IP Suit
Sagent has filed an Abbreviated New Drug Application with the the U.S. Food and Drug Administration seeking approval to make a generic version of Adenoscan, according to Astellas.
The patent-in-suit is U.S. Patent No. 5,731,296, “a selective vasodilation by continuous adenosine infusion” that is set to expire in...
To view the full article, register now.